Patient-reported outcomes in HIV clinical trials evaluating antiretroviral treatment: a systematic review
- 3 December 2020
- journal article
- review article
- Published by Taylor & Francis in AIDS Care
- Vol. 33 (9) , 1118-1126
Abstract
We aimed to assess patterns of patient-reported outcomes (PRO) instruments’ utilization in HIV clinical trials in relation to antiretroviral therapy (ART). PubMed/MEDLINE, Scopus, and EMBASE were searched using the terms “Patient-Reported Outcomes” and “HIV/AIDS” or “Antiretroviral Treatment” or “ART” or “Antiretroviral Therapy” from 1 January 1990 until 1 December 2019. In total, 173 studies were identified and 26 were directly related to ART. Study population included treatment-naïve patients (n = 4), treatment-experienced (n = 20), or both (n = 2). Instruments were implemented to assess general experience with ART (n = 3), single-tablet regimens (STR) (n = 2), monotherapy (n = 4), regimen switch (n = 9), or regimen comparison (n = 8). The most commonly used instruments were Medical Outcomes Study-HIV Health Survey (MOS–HIV, n = 8), HIV Symptom Index (HIV-SI, n = 7) and unstructured self-reports (n = 5) followed by others. MOS–HIV was used mainly in comparative (n = 4) and monotherapy (n = 3) trials, HIV-SI in switch (n = 4) and STR (n = 2) trials, and self-reports in comparative trials (n = 3). Even though, the implementation of PRO tools is increasing with time, reporting of PRO in HIV clinical trials remains limited.Keywords
Funding Information
- Gilead Sciences Hellas (80735)
This publication has 43 references indexed in Scilit:
- Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PIHIV Research & Clinical Practice, 2017
- Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week TrialThe Patient - Patient-Centered Outcomes Research, 2015
- The Use of Patient-reported Outcomes (PRO) Within Comparative Effectiveness ResearchMedical Care, 2012
- Pilot, Randomized Study Assessing Safety, Tolerability and Efficacy of Simplified LPV/r Maintenance Therapy in HIV Patients on the 1st PI-Based RegimenPLOS ONE, 2011
- Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenzAIDS Care, 2011
- Switch from protease inhibitor- to efavirenz-based antiretroviral therapy improves quality of life, treatment satisfaction and adherence with low rates of virological failure in virologically suppressed patientsInternational Journal of STD & AIDS, 2010
- Simplification of Antiretroviral Therapy to a Single-Tablet Regimen Consisting of Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate Versus Unmodified Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected PatientsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- Quality of life outcomes of combination zidovudine–didanosine–nevirapine and zidovudine–didanosine for antiretroviral-naive advanced HIV-infected patientsAIDS, 2000
- Quality of Life and Treatment Satisfaction After the Addition of Lamivudine or Lamivudine plus Loviride to Zidovudine-Containing Regimens in Treatment-Experienced Patients with HIV InfectionPharmacoEconomics, 1999
- A randomized trial of the effect of ritonavir in maintaining quality of life in advanced HIV diseaseAIDS, 1998